Recent Patents on Biomarkers

Back

Urine IL-18 is a Biomarker of Early Acute Kidney Injury (AKI)

Author(s): Charles L. Edelstein.

Abstract:

BUN and serum creatinine are not very sensitive and specific markers for the diagnosis of AKI as they are influenced by many renal and non-renal factors independent of kidney function. IL-18 is released into the urine by the injured kidney, analogous to the troponin release by injured myocardial cells after myocardial infarction, and is a more sensitive and specific early marker of AKI than BUN and serum creatinine. The most recent data on urine IL-18 comes from the Translational Research Investigating Biomarker Endpoints for Acute Kidney Injury (TRIBE-AKI) study. In 311 children and 1219 adults, urine IL-18 was increased in the first 6 hours after cardiac surgery in AKI patients that later developed a doubling of serum creatinine or the need for dialysis. In 2006, a patent was issued to inventors Charles L. Edelstein and Chirag R. Parikh entitled “Methods for detection of IL-18 as an early marker for the diagnosis of acute renal failure and predictor of mortality”. In addition to IL-18, patents have been issued for neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), Netrin-1, Gro-alpha (also known as CXCL1), heat shock protein-72, mannose- binding lectin (MBL), urinary cytokines and chemokines, aprotinin, and microalbumin as early diagnostic biomarkers of AKI. Also, there is a patent application for using proteomics for the discovery of biomarkers for the early detection of renal disease.

Keywords: Acute kidney injury, biomarker, interleukin-18, ischemic AKI, HMGB1, Interstitial inflammation, Cytokines, nephrotic syndrome, urinary tract infections.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 2
ISSUE: 3
Year: 2012
Page: [196 - 201]
Pages: 6
DOI: 10.2174/2210309011202030196
Price: $100